| 1943 | Humans |
| 1793 | Parkinson Disease |
| 1194 | Male |
| 1056 | Female |
| 937 | Middle Aged |
| 908 | Aged |
| 544 | Animals |
| 417 | Adult |
| 358 | Antiparkinson Agents |
| 356 | Levodopa |
| 277 | Subthalamic Nucleus |
| 233 | Deep Brain Stimulation |
| 231 | Dopamine |
| 230 | Aged, 80 and over |
| 218 | Neurons |
| 202 | Brain |
| 183 | Disease Models, Animal |
| 179 | Treatment Outcome |
| 167 | Rats |
| 147 | Substantia Nigra |
| 146 | Neuropsychological Tests |
| 142 | Corpus Striatum |
| 140 | France |
| 129 | Electric Stimulation Therapy |
| 123 | Parkinson Disease, Secondary |
| 121 | Severity of Illness Index |
| 112 | Magnetic Resonance Imaging |
| 111 | Mice |
| 108 | Dyskinesia, Drug-Induced |
| 99 | Case-Control Studies |
| 96 | Basal Ganglia |
| 95 | Time Factors |
| 93 | Follow-Up Studies |
| 90 | Dopamine Agonists |
| 89 | Alzheimer Disease |
| 88 | Electrodes, Implanted |
| 86 | Cognition Disorders |
| 79 | Oxidopamine |
| 78 | Tyrosine 3-Monooxygenase |
| 78 | Motor Activity |
| 77 | Globus Pallidus |
| 77 | Adolescent |
| 76 | alpha-Synuclein |
| 76 | Movement |
| 75 | Parkinsonian Disorders |
| 75 | Mutation |
| 73 | Risk Factors |
| 72 | Prospective Studies |
| 72 | Dementia |
| 71 | Wolff-Parkinson-White Syndrome |
| 70 | Reaction Time |
| 70 | Dopamine Agents |
| 68 | Nerve Degeneration |
| 68 | Double-Blind Method |
| 66 | Brain Mapping |
| 65 | Immunohistochemistry |
| 64 | Neurodegenerative Diseases |
| 63 | Retrospective Studies |
| 62 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 61 | Rats, Sprague-Dawley |
| 61 | Neurologic Examination |
| 61 | Movement Disorders |
| 61 | Functional Laterality |
| 61 | Dose-Response Relationship, Drug |
| 61 | Analysis of Variance |
| 60 | Psychomotor Performance |
| 60 | Disease Progression |
| 59 | Nerve Tissue Proteins |
| 59 | Mesencephalon |
| 58 | Tremor |
| 58 | Neural Pathways |
| 57 | Cognition |
| 53 | Stereotaxic Techniques |
| 53 | Rats, Wistar |
| 52 | Reference Values |
| 52 | Neuroprotective Agents |
| 52 | Genetic Predisposition to Disease |
| 51 | Quality of Life |
| 51 | Electrocardiography |
| 51 | Diagnosis, Differential |
| 51 | Cerebral Cortex |
| 50 | Dopaminergic Neurons |
| 50 | Child |
| 49 | Mice, Inbred C57BL |
| 49 | Gait Disorders, Neurologic |
| 48 | Surveys and Questionnaires |
| 48 | Apomorphine |
| 47 | Electromyography |
| 46 | Young Adult |
| 46 | Depression |
| 45 | Gait |
| 45 | Behavior, Animal |
| 44 | Cell Death |
| 43 | Reproducibility of Results |
| 43 | Motor Cortex |
| 43 | Electroencephalography |
| 43 | Electric Stimulation |
| 43 | Cross-Sectional Studies |
| 42 | Receptors, Dopamine D2 |
| 42 | Frontal Lobe |
| 41 | Supranuclear Palsy, Progressive |
| 41 | Positron-Emission Tomography |
| 41 | Drug Therapy, Combination |
| 41 | Age of Onset |
| 40 | Tomography, Emission-Computed, Single-Photon |
| 40 | Age Factors |
| 39 | Ubiquitin-Protein Ligases |
| 39 | Psychiatric Status Rating Scales |
| 39 | Genotype |
| 37 | RNA, Messenger |
| 37 | MPTP Poisoning |
| 37 | Activities of Daily Living |
| 36 | Thalamic Nuclei |
| 36 | Statistics, Nonparametric |
| 36 | Prevalence |
| 36 | Posture |
| 36 | Macaca fascicularis |
| 36 | Clinical Trials as Topic |
| 35 | Thalamus |
| 34 | Signal Transduction |
| 34 | Receptors, Dopamine |
| 34 | Mitochondria |
| 34 | Apoptosis |
| 33 | Postural Balance |
| 33 | Multiple System Atrophy |
| 33 | Dopamine Plasma Membrane Transport Proteins |
| 32 | Mental Disorders |
| 32 | Lewy Bodies |
| 32 | Dyskinesias |
| 32 | Cohort Studies |
| 32 | Attention |
| 31 | Neurosurgical Procedures |
| 31 | Emotions |
| 31 | Electrophysiology |
| 30 | REM Sleep Behavior Disorder |
| 30 | Gene Expression Regulation |
| 30 | Europe |
| 29 | Tomography, Emission-Computed |
| 29 | Disability Evaluation |
| 29 | Aging |
| 28 | Protein-Serine-Threonine Kinases |
| 28 | Mice, Knockout |
| 28 | Memory |
| 28 | Image Processing, Computer-Assisted |
| 28 | Combined Modality Therapy |
| 28 | Bromocriptine |
| 27 | tau Proteins |
| 27 | Nerve Net |
| 27 | Cells, Cultured |
| 27 | Catheter Ablation |
| 26 | Predictive Value of Tests |
| 26 | Polysomnography |
| 26 | Phenotype |
| 26 | Models, Neurological |
| 26 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
| 26 | Genetic Therapy |
| 26 | Apathy |
| 25 | Photic Stimulation |
| 25 | Huntington Disease |
| 25 | Depressive Disorder |
| 24 | Prognosis |
| 24 | Muscle, Skeletal |
| 24 | Dystonia |
| 24 | Cerebrovascular Circulation |
| 24 | Carrier Proteins |
| 24 | Basal Ganglia Diseases |
| 23 | Sensitivity and Specificity |
| 23 | Receptors, Dopamine D1 |
| 23 | Polymorphism, Single Nucleotide |
| 23 | Pedigree |
| 23 | Oxidative Stress |
| 23 | Neuronal Plasticity |
| 23 | Neuroglia |
| 23 | Models, Biological |
| 23 | Incidence |
| 23 | Heart Conduction System |
| 22 | Nervous System Diseases |
| 22 | Neostriatum |
| 22 | Muscle Rigidity |
| 22 | In Situ Hybridization |
| 22 | DNA Mutational Analysis |
| 22 | Comorbidity |
| 22 | Child, Preschool |
| 22 | Cell Count |
| 22 | Antipsychotic Agents |
| 21 | Neurology |
| 21 | Biomechanical Phenomena |
| 21 | Atrial Fibrillation |
| 20 | Tomography, X-Ray Computed |
| 20 | Synaptic Transmission |
| 20 | Sleep Wake Disorders |
| 20 | Recognition (Psychology) |
| 20 | Pilot Projects |
| 20 | Norepinephrine |
| 20 | Drug Administration Schedule |
| 20 | Brain Chemistry |
| 19 | Synucleins |
| 19 | Radiopharmaceuticals |
| 19 | Motivation |
| 19 | Lewy Body Disease |
| 19 | Hypotension, Orthostatic |
| 19 | History, 20th Century |
| 19 | History, 19th Century |
| 19 | Dopamine Antagonists |
| 19 | Disruptive, Impulse Control, and Conduct Disorders |
| 19 | Arrhythmias, Cardiac |
| 19 | Anxiety |
| 19 | Amyotrophic Lateral Sclerosis |
| 19 | Action Potentials |
| 18 | Serotonin |
| 18 | Putamen |
| 18 | Polymorphism, Genetic |
| 18 | Pedunculopontine Tegmental Nucleus |
| 18 | Neurotoxins |
| 18 | Motor Skills |
| 18 | Mice, Transgenic |
| 18 | Memory Disorders |
| 18 | Membrane Glycoproteins |
| 18 | Longitudinal Studies |
| 18 | Iron |
| 18 | Facial Expression |
| 18 | Electrophysiologic Techniques, Cardiac |
| 18 | Cell Survival |
| 18 | Biomarkers |
| 17 | Piribedil |
| 17 | Pain |
| 17 | Mental Recall |
| 17 | Membrane Transport Proteins |
| 17 | Macaca mulatta |
| 17 | Hallucinations |
| 17 | Genetic Vectors |
| 17 | Drug Interactions |
| 17 | Dominance, Cerebral |
| 17 | Cross-Over Studies |
| 17 | Cortical Synchronization |
| 17 | Blood Pressure |
| 16 | Sex Factors |
| 16 | Protein Kinases |
| 16 | Postoperative Complications |
| 16 | Phosphorylation |
| 16 | Multivariate Analysis |
| 16 | Mental Status Schedule |
| 16 | Kinetics |
| 16 | Indoles |
| 16 | Hypokinesia |
| 16 | Heart Rate |
| 16 | Glutamic Acid |
| 16 | Denervation |
| 16 | Autonomic Nervous System Diseases |
| 15 | gamma-Aminobutyric Acid |
| 15 | Visual Perception |
| 15 | United States |
| 15 | Speech |
| 15 | Regression Analysis |
| 15 | Mood Disorders |
| 15 | Molecular Sequence Data |
| 15 | Locomotion |
| 15 | Iodine Radioisotopes |
| 15 | Inflammation |
| 15 | Indans |
| 15 | Gene Expression |
| 15 | Family Health |
| 15 | Enzyme Inhibitors |
| 15 | Dysarthria |
| 15 | Dihydroxyphenylalanine |
| 15 | Cerebellum |
| 15 | Catechols |
| 15 | Algorithms |
| 14 | Up-Regulation |
| 14 | Sympatholytics |
| 14 | Statistics as Topic |
| 14 | Randomized Controlled Trials as Topic |
| 14 | Protein Binding |
| 14 | Polymerase Chain Reaction |
| 14 | Pesticides |
| 14 | Pattern Recognition, Visual |
| 14 | Multiple Sclerosis |
| 14 | Imaging, Three-Dimensional |
| 14 | Chronic Disease |
| 14 | Caudate Nucleus |
| 14 | Blotting, Western |
| 14 | Autoradiography |
| 14 | Adrenergic Agents |
| 14 | Accidental Falls |
| 13 | Walking |
| 13 | Transcription Factors |
| 13 | Transcranial Magnetic Stimulation |
| 13 | Temporal Lobe |
| 13 | Task Performance and Analysis |
| 13 | Tachycardia |
| 13 | Receptors, Dopamine D3 |
| 13 | Patient Selection |
| 13 | Odds Ratio |
| 13 | Nitriles |
| 13 | Neurotransmitter Agents |
| 13 | Neurofibrillary Tangles |
| 13 | Nerve Growth Factors |
| 13 | Mutation, Missense |
| 13 | Glial Cell Line-Derived Neurotrophic Factor |
| 13 | Fluorodeoxyglucose F18 |
| 13 | Fetal Tissue Transplantation |
| 13 | Excitatory Amino Acid Antagonists |
| 13 | Electron Transport Complex IV |
| 13 | Drug Combinations |
| 13 | Cell Line |
| 13 | Calcium |
| 13 | Atrophy |
| 12 | Tachycardia, Supraventricular |
| 12 | Synapses |
| 12 | Smoking |
| 12 | Sleep, REM |
| 12 | Schizophrenia |
| 12 | Monitoring, Intraoperative |
| 12 | Logistic Models |
| 12 | Learning |
| 12 | Infant |
| 12 | Haplorhini |
| 12 | Glucose |
| 12 | Gene Frequency |
| 12 | Epilepsy |
| 12 | Enteric Nervous System |
| 12 | Disorders of Excessive Somnolence |
| 12 | Benzothiazoles |
| 12 | Antidepressive Agents |
| 12 | Amino Acid Sequence |
| 12 | Affect |
| 12 | Adaptation, Psychological |
| 12 | 1-Methyl-4-phenylpyridinium |
| 11 | Space Perception |
| 11 | Selegiline |
| 11 | Riluzole |
| 11 | Radionuclide Imaging |
| 11 | ROC Curve |
| 11 | Proto-Oncogene Proteins c-fos |
| 11 | Prefrontal Cortex |
| 11 | Point Mutation |
| 11 | Piperidines |
| 11 | Pain Measurement |
| 11 | Occupational Exposure |
| 11 | Obsessive-Compulsive Disorder |
| 11 | Intracellular Signaling Peptides and Proteins |
| 11 | Image Interpretation, Computer-Assisted |
| 11 | Glutamate Decarboxylase |
| 11 | Genes, Recessive |
| 11 | Executive Function |
| 11 | Environmental Exposure |
| 11 | Drug Resistance |
| 11 | Cues |
| 11 | Confidence Intervals |
| 11 | Chromatography, High Pressure Liquid |
| 11 | Cell Transplantation |
| 11 | Cell Line, Tumor |
| 11 | Carbidopa |
| 11 | Brain Tissue Transplantation |
| 11 | Brain Diseases |
| 11 | Axons |
| 11 | Autophagy |
| 11 | Age Distribution |
| 11 | 3,4-Dihydroxyphenylacetic Acid |
| 10 | Weight Gain |
| 10 | Verbal Learning |
| 10 | Tumor Suppressor Protein p53 |
| 10 | Saccades |
| 10 | Reward |
| 10 | Psychotic Disorders |
| 10 | Paris |
| 10 | Olfaction Disorders |
| 10 | Neuroblastoma |
| 10 | Motor Neurons |
| 10 | Monoamine Oxidase Inhibitors |
| 10 | Microsatellite Repeats |
| 10 | Microglia |
| 10 | Melanins |
| 10 | Macaca |
| 10 | Homeodomain Proteins |
| 10 | Hippocampus |
| 10 | Heterozygote |
| 10 | Heart Diseases |
| 10 | Hand |
| 10 | Eye Movements |
| 10 | Exons |
| 10 | Evoked Potentials, Motor |
| 10 | Energy Metabolism |
| 10 | Decision Making |
| 10 | Central Nervous System |
| 10 | Catecholamines |
| 10 | Brain Stem |
| 10 | Binding Sites |
| 10 | Behavior |
| 10 | Administration, Oral |
| 9 | Ventral Tegmental Area |
| 9 | Thiazoles |
| 9 | Stereotyped Behavior |
| 9 | Sex Distribution |
| 9 | Sensation Disorders |
| 9 | Receptors, Metabotropic Glutamate |
| 9 | Pyridines |
| 9 | Psychometrics |
| 9 | Proteins |
| 9 | Piperazines |
| 9 | Peripheral Nervous System Diseases |
| 9 | Pergolide |
| 9 | Oxidation-Reduction |
| 9 | Outcome Assessment (Health Care) |
| 9 | Orientation |
| 9 | Organ Specificity |
| 9 | Oncogene Proteins |
| 9 | Microscopy, Electron |
| 9 | Limbic System |
| 9 | Leg |
| 9 | Injections, Subcutaneous |
| 9 | Homovanillic Acid |
| 9 | Haplotypes |
| 9 | Genetic Variation |
| 9 | Genes, Dominant |
| 9 | Fluorine Radioisotopes |
| 9 | Evoked Potentials |
| 9 | European Continental Ancestry Group |
| 9 | Essential Tremor |
| 9 | Epinephrine |
| 9 | Enkephalins |
| 9 | Databases, Factual |
| 9 | DNA-Binding Proteins |
| 9 | Computer Simulation |
| 9 | Chi-Square Distribution |
| 9 | Bipolar Disorder |
| 9 | Base Sequence |
| 9 | Anxiety Disorders |
| 9 | Amino Acid Substitution |
| 9 | Alleles |
| 9 | Adaptation, Physiological |
| 9 | Acoustic Stimulation |
| 8 | Wakefulness |
| 8 | Video Recording |
| 8 | Time |
| 8 | Time Perception |
| 8 | Speech Disorders |
| 8 | Signal Processing, Computer-Assisted |
| 8 | Rotenone |
| 8 | Risk Assessment |
| 8 | Recovery of Function |
| 8 | Reactive Oxygen Species |
| 8 | Radiography |
| 8 | Protein Deglycase DJ-1 |
| 8 | Promoter Regions, Genetic |
| 8 | Prions |
| 8 | Practice Guidelines as Topic |
| 8 | Placebos |
| 8 | Neoplasms |
| 8 | Myoclonus |
| 8 | Motor Skills Disorders |
| 8 | Models, Statistical |
| 8 | Models, Molecular |
| 8 | Ligases |
| 8 | Isoenzymes |
| 8 | International Cooperation |
| 8 | Genome-Wide Association Study |
| 8 | Genetic Testing |
| 8 | Gene Transfer Techniques |
| 8 | Gambling |
| 8 | Extracellular Space |
| 8 | Echocardiography |
| 8 | Dopamine Uptake Inhibitors |
| 8 | Delayed-Action Preparations |
| 8 | Death, Sudden, Cardiac |
| 8 | Data Interpretation, Statistical |
| 8 | Cytochrome P-450 CYP2D6 |
| 8 | Cost-Benefit Analysis |
| 8 | Cluster Analysis |
| 8 | Circadian Rhythm |
| 8 | Cell Differentiation |
| 8 | Catalepsy |
| 8 | Caspases |
| 8 | Brain Injuries |
| 8 | Body Weight |
| 8 | Amyloid beta-Peptides |
| 8 | Adenoviridae |
| 7 | Ubiquitin |
| 7 | Tritium |
| 7 | Tissue Distribution |
| 7 | Tetrahydronaphthalenes |
| 7 | Tetrabenazine |
| 7 | Syndrome |
| 7 | Superoxide Dismutase |
| 7 | Substance-Related Disorders |
| 7 | Stroke |
| 7 | Stem Cells |
| 7 | Stem Cell Transplantation |
| 7 | Solubility |
| 7 | Sleep |
| 7 | Sleep Stages |
| 7 | Serotonin Receptor Agonists |
| 7 | Serine |
| 7 | Semantics |
| 7 | Regional Blood Flow |
| 7 | Recurrence |
| 7 | Receptors, Neurotransmitter |
| 7 | Protein Processing, Post-Translational |
| 7 | Protein Precursors |
| 7 | Protein Folding |
